<?xml version="1.0" encoding="UTF-8"?>
<p id="p0225">Almost 40 years after the first discovery of a natural flavagline in 1982, a synthetic one zotatifin, developed by eFFECTOR, has reached phase 1/2 clinical trial in cancer patients. This company is now exploring with members of the biopharmaceutical and scientific communities, NIAID and funding sources as to how to explore the potential of zotatifin against COVID-19.</p>
